Audrey Greenberg is a recognized leader in the biotech industry, having been selected as a Top Trailblazer, Titan 100, Healthcare Power Player, and Woman of Distinction. With a proven track record of building life science companies through capital attraction, strategic relationships, novel technologies, and top-tier management teams, Audrey is also a renowned keynote speaker specializing in Cell and Gene Therapy, DEI initiatives, “Cellicon Valley,” and building bioinnovation hubs. She is a champion of women’s leadership causes and a mentor to aspiring young professionals.
As the Founder and Chief Business Officer of the Center for Breakthrough Medicines (CBM), Audrey is responsible for business development, corporate strategy, team attraction and engagement, and joint venture and investor relationships. In just two years, Audrey launched CBM, attracted 400 employees from around the globe, raised $350 million in capital, and negotiated and closed a 15-year $100 million joint venture with the University of Pennsylvania’s Gene Therapy Program. CBM has received several awards, including Employer of the Year, Startup of the Year, Innovator Company of the Year, and DEI Initiative of the Year.
Before launching CBM, Audrey founded Discovery Labs, which grew to become the largest privately held life science real estate portfolio in the United States. She also spent two decades as an executive in private equity, where she grew assets under management to over $100 billion. Audrey began her career excelling in the investment banking field, having closed several notable transactions in the financial services industry.
Audrey serves as an independent board member at three companies and advises eight global industry organizations. She is the chair of the governance and nominating committee and a member of the audit committee at New York Mortgage Trust (NASDAQ: NYMT). Audrey is also an advisory board member and active participant in several organizations, including the Abramson Cancer Center Innovation Advisory Board at Penn Medicine, Phacilitate Advisory Board, PACT FemTech Advisory Board, ISPE Owner Advisory Group, The Woman’s Executive Forum at the Alliance for Regenerative Medicine, Woman in Bio Executive Roundtable, ISCT Global Industry Committee, Circle of Advisors to Healthcare Businesswomen’s Association, the Greater Philadelphia Chamber’s Diverse Procurement Collaborative, Philadelphia Skills Forward Initiative, and the CEO Council for Growth’s Cell and Gene Therapy and Connected Health Initiative.